Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Gains from Sales and Divestitures (2019 - 2025)

Assembly Biosciences has reported Gains from Sales and Divestitures over the past 7 years, most recently at $18855.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $18855.0 for Q4 2025, down 63.65% from a year ago — trailing twelve months through Dec 2025 was $18855.0 (down 63.65% YoY), and the annual figure for FY2025 was $18855.0, down 63.65%.
  • Gains from Sales and Divestitures for Q4 2025 was $18855.0 at Assembly Biosciences, down from $51872.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for ASMB hit a ceiling of $347096.0 in Q4 2021 and a floor of $18855.0 in Q4 2025.
  • Median Gains from Sales and Divestitures over the past 5 years was $135929.0 (2021), compared with a mean of $146093.9.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 52.24% in 2021 and later tumbled 82.8% in 2023.
  • Assembly Biosciences' Gains from Sales and Divestitures stood at $347096.0 in 2021, then decreased by 28.15% to $249376.0 in 2022, then tumbled by 82.8% to $42898.0 in 2023, then rose by 20.92% to $51872.0 in 2024, then plummeted by 63.65% to $18855.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $18855.0 (Q4 2025), $51872.0 (Q4 2024), and $42898.0 (Q4 2023) per Business Quant data.